Q-omics provides the consensus-scored LRRC47 profile across patient tissues and cancer cell-line models. LRRC47 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, LRRC47 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, LRRC47 protein abundance shows 25,406 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KICH, COAD, and GBM as cancer lineages where LRRC47 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC47 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC47 survival associations across molecular data types. LRRC47 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC47 RNA expression–survival associations across cancer types. High LRRC47 expression shows unfavorable associations in KICH, ACC and LIHC, but favorable associations in KIRC, CHOL and SCLC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for LRRC47 RNA expression.
This table summarizes LRRC47 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 10. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for LRRC47. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC47 shows lower tumor expression in KICH and THCA and higher tumor expression in COAD, LUSC, LIHC and HNSC. The COAD box plot shows higher LRRC47 RNA expression in tumor versus normal tissue (log2 FC = +0.492, t-test p < 0.001).
This table shows molecular features associated with LRRC47 in patient tissues and cancer cell lines. In patient samples, LRRC47 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC47 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
